<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01357577</url>
  </required_header>
  <id_info>
    <org_study_id>SPLA-01-S09</org_study_id>
    <nct_id>NCT01357577</nct_id>
  </id_info>
  <brief_title>Cognitive Behavioral Therapy (CBT) for PTSD in Veterans With Co-Occurring SUDs</brief_title>
  <acronym>CBT</acronym>
  <official_title>CBT for PTSD in Veterans With Co-Occurring Substance Use Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      With this research, the investigators hope to learn if cognitive behavioral therapy (CBT) for
      posttraumatic stress disorder (PTSD) works in people who have both PTSD and problems with
      drugs or alcohol. In the past, people who had problems with drugs and alcohol were not given
      treatment for their PTSD. It was believed that PTSD treatment would get in the way of their
      drug and alcohol treatment. Now the investigators believe that the PTSD symptoms may make it
      harder to avoid using drugs and alcohol, so the investigators want to see if people can get
      treatment for both problems at the same time.

      One hundred-sixty Veterans from 3 sites who have both PTSD and substance use disorders will
      be in the study. In order to know if the PTSD treatment is helpful, half of the Veterans in
      this study will receive PTSD treatment and half will continue to get their usual mental
      health and/or substance abuse treatment. Who gets which treatment will be decided by a random
      process. The investigators will then compare the 2 groups to see if there are differences in
      their PTSD symptoms.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized clinical trial to evaluate the effectiveness of a relatively simple,
      manual-guided cognitive behavioral therapy (CBT) for PTSD in patients with substance use
      disorders (SUDs). One hundred sixty outpatients with comorbid PTSD and SUDs from three VA
      facilities will be randomly assigned to receive either CBT for PTSD in conjunction with
      standard treatment as usual (TAU) (n = 80) or TAU only (n = 80).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2013</start_date>
  <completion_date type="Actual">October 31, 2017</completion_date>
  <primary_completion_date type="Actual">October 31, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CAPS Total Score Analysis Among Participants Completing at Least One Follow-up Assessment.</measure>
    <time_frame>Conclusion of treatment (post-treatment occurs approximately 4-months after treatment conclusion) and 6 months follow-up</time_frame>
    <description>PTSD symptom severity will be measured by the Clinician Administered PTSD Scale (CAPS). The Clinician Administered PTSD SCALE (CAPS) is the gold standard in PTSD assessment. It is a structured interview that can be used to: Make current (past month) diagnosis of PTSD and Make lifetime diagnosis of PTSD. The minimum value is a 0 and the maximum is 135, the higher the score the worse the outcome, i.e. the more severe PTSD.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Addiction Severity Index (Alcohol Addiction)</measure>
    <time_frame>Baseline, Post-Treatment (approximately 4-months after treatment conclusion), and 6-Months</time_frame>
    <description>The ASI is a standardized, structured interview that assesses past 30 days problem severity in seven areas. These seven areas include medical, employment, drug, alcohol, legal, family/social and psychiatric status. Problem severity is rated on a scale of 0.0 - 1.0 with a higher score indicative of more problem severity. All scales have a range from 0 to 1.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Addiction Severity Index (Drug Use)</measure>
    <time_frame>Baseline, Post-Treatment (approximately 4-months after treatment conclusion), and 6-Months</time_frame>
    <description>The ASI is a standardized, structured interview that assesses past 30 days problem severity in seven areas. These seven areas include medical, employment, drug, alcohol, legal, family/social and psychiatric status. Problem severity is rated on a scale of 0.0 - 1.0 with a higher score indicative of more problem severity. All scales have a range from 0 to 1.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PTSD Checklist (PCL)</measure>
    <time_frame>Baseline, Post-Treatment (approximately 4-months post treatment completion), 6-months</time_frame>
    <description>A secondary measure of PTSD will be the PCL. The PCL is a widely used self-report measure that assesses the 17 DSM-IV PTSD symptoms. Responses to these questions are on a scale of 1 to 5 (&quot;not at all&quot; to &quot;extremely&quot;). A total symptom severity score (range from 17-85) can be calculated, with a higher score indicating higher symptom severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Health Questionnaire-9 (PHQ-9)</measure>
    <time_frame>Baseline, Post-Treatment (approximately 4-months post treatment completion), 6 months</time_frame>
    <description>Patient Health Questionnaire-9 (PHQ-9): The PHQ-9 is adapted from the PRIME-MD. It can be used as a screen for depression or as a severity measure. The investigators used it as a measure of severity. The PHQ-9 score is on a range of 0 to 27, where a higher score indicates higher severity.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">129</enrollment>
  <condition>PTSD</condition>
  <condition>Substance Use Disorders</condition>
  <arm_group>
    <arm_group_label>Arm 1: TAU + CBT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The experimental group will receive treatment as usual (TAU) plus cognitive behavioral therapy (CBT).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2: TAU</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The &quot;no intervention&quot; group will receive treatment as usual (TAU).</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Cognitive behavioral therapy for PTSD</intervention_name>
    <description>The CBT for PTSD model is based on modern theories of posttraumatic reactions that place a premium on the importance of individuals' appraisals of traumatic events, their own reactions and those of others, and the meaning of the experience in terms of oneself and one's place in the world. In addition, the model employs cognitive restructuring to teach individuals how to examine and challenge their trauma-related appraisals.</description>
    <arm_group_label>Arm 1: TAU + CBT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At least age 18.

          -  Current SUD diagnosis.

          -  Score of at least 45 on CAPS.

          -  Must speak English.

          -  Must agree to be taped.

        Exclusion Criteria:

          -  Acute psychotic symptoms, if not well connected with appropriate mental health
             services.

          -  Severe suicidality.

          -  Individuals with unstable medical or legal situations that would make completion of
             the study highly unlikely.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jessica L Hamblen, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>White River Junction VA Medical Center, White River Junction, VT</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>James A. Haley Veterans' Hospital, Tampa, FL</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Syracuse VA Medical Center, Syracuse, NY</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>White River Junction VA Medical Center, White River Junction, VT</name>
      <address>
        <city>White River Junction</city>
        <state>Vermont</state>
        <zip>05009-0001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>May 18, 2011</study_first_submitted>
  <study_first_submitted_qc>May 18, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 20, 2011</study_first_posted>
  <results_first_submitted>December 2, 2019</results_first_submitted>
  <results_first_submitted_qc>January 17, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">January 29, 2020</results_first_posted>
  <last_update_submitted>January 17, 2020</last_update_submitted>
  <last_update_submitted_qc>January 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PTSD</keyword>
  <keyword>Substance Use Disorders</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Substance-Related Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 15, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/77/NCT01357577/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited from three Veteran Affairs Medical Centers (VAMC): Syracuse, NY VAMC; Tampa Bay, FL VAMC; and White River Junction, VT VAMC. Participants were recruited from outpatient and inpatient clinics at the three respective facilities.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Cognitive Behavioral Therapy (CBT) + Treatment as Usual (TAU)</title>
          <description>The experimental group will receive treatment as usual (TAU) plus cognitive behavioral therapy (CBT).
Cognitive behavioral therapy for PTSD: The CBT for PTSD model is based on modern theories of posttraumatic reactions that place a premium on the importance of individuals' appraisals of traumatic events, their own reactions and those of others, and the meaning of the experience in terms of oneself and one's place in the world. In addition, the model employs cognitive restructuring to teach individuals how to examine and challenge their trauma-related appraisals.</description>
        </group>
        <group group_id="P2">
          <title>Treatment as Usual (TAU)</title>
          <description>The &quot;no intervention&quot; group will receive treatment as usual (TAU).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="64"/>
                <participants group_id="P2" count="65"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Post-Treatment Assessment Completed</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>look at data in database?</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cognitive Behavioral Therapy + Treatment as Usual</title>
          <description>The experimental group will receive treatment as usual (TAU) plus cognitive behavioral therapy (CBT).
Cognitive behavioral therapy for PTSD: The CBT for PTSD model is based on modern theories of posttraumatic reactions that place a premium on the importance of individuals' appraisals of traumatic events, their own reactions and those of others, and the meaning of the experience in terms of oneself and one's place in the world. In addition, the model employs cognitive restructuring to teach individuals how to examine and challenge their trauma-related appraisals.</description>
        </group>
        <group group_id="B2">
          <title>Treatment as Usual</title>
          <description>The &quot;no intervention&quot; group will receive treatment as usual (TAU) without additional individual treatment..</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="64"/>
            <count group_id="B2" value="65"/>
            <count group_id="B3" value="129"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                    <measurement group_id="B2" value="65"/>
                    <measurement group_id="B3" value="129"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Age (years)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.2" spread="12.5"/>
                    <measurement group_id="B2" value="45.9" spread="11.5"/>
                    <measurement group_id="B3" value="44.2" spread="12.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="115"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="88"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <description>As previously indicated, all participants were recruited three VAMCs in the United States: Syracuse, NY; White River Junction, VT; and Tampa, FL.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                    <measurement group_id="B2" value="65"/>
                    <measurement group_id="B3" value="129"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>CAPS Total Score Analysis Among Participants Completing at Least One Follow-up Assessment.</title>
        <description>PTSD symptom severity will be measured by the Clinician Administered PTSD Scale (CAPS). The Clinician Administered PTSD SCALE (CAPS) is the gold standard in PTSD assessment. It is a structured interview that can be used to: Make current (past month) diagnosis of PTSD and Make lifetime diagnosis of PTSD. The minimum value is a 0 and the maximum is 135, the higher the score the worse the outcome, i.e. the more severe PTSD.</description>
        <time_frame>Conclusion of treatment (post-treatment occurs approximately 4-months after treatment conclusion) and 6 months follow-up</time_frame>
        <population>Our intention-to-treat analysis has N=80 patients (33 CBT; 47 control): It consists of patients with at least one follow-up (post or 6-mo) assessment (e.g., of the 64 participants randomized to CBT, 24 and 27 had a CAPS assessment at post and 6 months, respectively, with 33 participants having at least one valid follow-up CAPS).</population>
        <group_list>
          <group group_id="O1">
            <title>Cognitive Behavioral Therapy + Treatment as Usual</title>
            <description>The experimental group will receive treatment as usual (TAU) plus cognitive behavioral therapy (CBT).
Cognitive behavioral therapy for PTSD: The CBT for PTSD model is based on modern theories of posttraumatic reactions that place a premium on the importance of individuals' appraisals of traumatic events, their own reactions and those of others, and the meaning of the experience in terms of oneself and one's place in the world. In addition, the model employs cognitive restructuring to teach individuals how to examine and challenge their trauma-related appraisals.</description>
          </group>
          <group group_id="O2">
            <title>Treatment as Usual</title>
            <description>The &quot;no intervention&quot; group will receive treatment as usual (TAU) without additional treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>CAPS Total Score Analysis Among Participants Completing at Least One Follow-up Assessment.</title>
          <description>PTSD symptom severity will be measured by the Clinician Administered PTSD Scale (CAPS). The Clinician Administered PTSD SCALE (CAPS) is the gold standard in PTSD assessment. It is a structured interview that can be used to: Make current (past month) diagnosis of PTSD and Make lifetime diagnosis of PTSD. The minimum value is a 0 and the maximum is 135, the higher the score the worse the outcome, i.e. the more severe PTSD.</description>
          <population>Our intention-to-treat analysis has N=80 patients (33 CBT; 47 control): It consists of patients with at least one follow-up (post or 6-mo) assessment (e.g., of the 64 participants randomized to CBT, 24 and 27 had a CAPS assessment at post and 6 months, respectively, with 33 participants having at least one valid follow-up CAPS).</population>
          <units>score on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CAPS Total Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="47"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.2" spread="18.4"/>
                    <measurement group_id="O2" value="78.0" spread="16.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CAPS Total Post-Treatment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.5" spread="26.3"/>
                    <measurement group_id="O2" value="71.0" spread="26.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CAPS Total 6 Months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                    <count group_id="O2" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.2" spread="21.6"/>
                    <measurement group_id="O2" value="62.9" spread="21.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>.48</p_value>
            <p_value_desc>P-Value show above is for post-assessment time point.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed-model p-values are adjusted for study site and the baseline total CAPS score.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>.12</p_value>
            <p_value_desc>The p-value shown above is for the 6-month time point.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed-model p-values are adjusted for study site and the baseline total CAPS score.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>.65</p_value>
            <p_value_desc>The p-value shown above refers to the treatment main effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>.072</p_value>
            <p_value_desc>The p-value shown above refers to the timepoint main effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>.0050</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>The p-value shown above refers to the interaction.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>.12</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>The p-value shown above refers to the site main effect.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Addiction Severity Index (Alcohol Addiction)</title>
        <description>The ASI is a standardized, structured interview that assesses past 30 days problem severity in seven areas. These seven areas include medical, employment, drug, alcohol, legal, family/social and psychiatric status. Problem severity is rated on a scale of 0.0 - 1.0 with a higher score indicative of more problem severity. All scales have a range from 0 to 1.0.</description>
        <time_frame>Baseline, Post-Treatment (approximately 4-months after treatment conclusion), and 6-Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cognitive Behavioral Therapy + Treatment as Usual</title>
            <description>The experimental group will receive treatment as usual (TAU) plus cognitive behavioral therapy (CBT).
Cognitive behavioral therapy for PTSD: The CBT for PTSD model is based on modern theories of posttraumatic reactions that place a premium on the importance of individuals' appraisals of traumatic events, their own reactions and those of others, and the meaning of the experience in terms of oneself and one's place in the world. In addition, the model employs cognitive restructuring to teach individuals how to examine and challenge their trauma-related appraisals.</description>
          </group>
          <group group_id="O2">
            <title>Treatment as Usual</title>
            <description>The &quot;no intervention&quot; group will receive treatment as usual (TAU) without additional individual treatment..</description>
          </group>
        </group_list>
        <measure>
          <title>Addiction Severity Index (Alcohol Addiction)</title>
          <description>The ASI is a standardized, structured interview that assesses past 30 days problem severity in seven areas. These seven areas include medical, employment, drug, alcohol, legal, family/social and psychiatric status. Problem severity is rated on a scale of 0.0 - 1.0 with a higher score indicative of more problem severity. All scales have a range from 0 to 1.0.</description>
          <units>score on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Alcohol Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".25" spread=".22"/>
                    <measurement group_id="O2" value=".25" spread=".25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alcohol Post-Treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".13" spread=".17"/>
                    <measurement group_id="O2" value=".17" spread=".22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alcohol 6-Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".18" spread=".18"/>
                    <measurement group_id="O2" value=".20" spread=".27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>mixed-effects linear regression model adjusted for study site and the baseline value of the dependent variable.</non_inferiority_desc>
            <p_value>.12</p_value>
            <p_value_desc>Post-treatment P-value.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed-model p-values are adjusted for study site and baseline ASI (Alcohol Use) score.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>.84</p_value>
            <p_value_desc>6-month P-Value.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed-model p-values adjusted for study site and Baseline ASI (Alcohol Use) score.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>.26</p_value>
            <p_value_desc>treatment main effect</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed-model p-values adjusted for study site and Baseline ASI (Alcohol Use) score.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>.14</p_value>
            <p_value_desc>Timepoint main effect P-value</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed-model p-values adjusted for study site and Baseline ASI (Alcohol Use) score.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>.29</p_value>
            <p_value_desc>interaction</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed-model p-values adjusted for study site and Baseline ASI (Alcohol Use) score.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>.16</p_value>
            <p_value_desc>Site main effect P-Value.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed-model p-values adjusted for study site and Baseline ASI (Alcohol Use) score.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Addiction Severity Index (Drug Use)</title>
        <description>The ASI is a standardized, structured interview that assesses past 30 days problem severity in seven areas. These seven areas include medical, employment, drug, alcohol, legal, family/social and psychiatric status. Problem severity is rated on a scale of 0.0 - 1.0 with a higher score indicative of more problem severity. All scales have a range from 0 to 1.0.</description>
        <time_frame>Baseline, Post-Treatment (approximately 4-months after treatment conclusion), and 6-Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cognitive Behavioral Therapy + Treatment as Usual</title>
            <description>The experimental group will receive treatment as usual (TAU) plus cognitive behavioral therapy (CBT).
Cognitive behavioral therapy for PTSD: The CBT for PTSD model is based on modern theories of posttraumatic reactions that place a premium on the importance of individuals' appraisals of traumatic events, their own reactions and those of others, and the meaning of the experience in terms of oneself and one's place in the world. In addition, the model employs cognitive restructuring to teach individuals how to examine and challenge their trauma-related appraisals.</description>
          </group>
          <group group_id="O2">
            <title>Treatment as Usual</title>
            <description>The &quot;no intervention&quot; group will receive treatment as usual (TAU) without additional individual treatment..</description>
          </group>
        </group_list>
        <measure>
          <title>Addiction Severity Index (Drug Use)</title>
          <description>The ASI is a standardized, structured interview that assesses past 30 days problem severity in seven areas. These seven areas include medical, employment, drug, alcohol, legal, family/social and psychiatric status. Problem severity is rated on a scale of 0.0 - 1.0 with a higher score indicative of more problem severity. All scales have a range from 0 to 1.0.</description>
          <units>score on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Drug Use Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".17" spread=".18"/>
                    <measurement group_id="O2" value=".10" spread=".11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drug Use Post-Treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".09" spread=".18"/>
                    <measurement group_id="O2" value=".08" spread=".13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drug Use 6-Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".11" spread=".15"/>
                    <measurement group_id="O2" value=".04" spread=".08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>.66</p_value>
            <p_value_desc>Post-treatment p-value.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed-model p-values are adjusted for study site and baseline ASI (drug score).</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>.53</p_value>
            <p_value_desc>6-month P-Value.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed model p-values are adjusted for study site and baseline ASI (Drug Use) score.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>.86</p_value>
            <p_value_desc>Treatment main effect P-Value.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed model p-values are adjusted for study site and baseline ASI (Drug Use) score.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>.16</p_value>
            <p_value_desc>Timepoint main effect P-Value.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed model p-values are adjusted for study site and baseline ASI (Drug Use) score.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>.47</p_value>
            <p_value_desc>Interaction P-Value.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed model p-values are adjusted for study site and baseline ASI (Drug Use) score.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>.19</p_value>
            <p_value_desc>Site main effect P-Value.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed model p-values are adjusted for study site and baseline ASI (Drug Use) score.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PTSD Checklist (PCL)</title>
        <description>A secondary measure of PTSD will be the PCL. The PCL is a widely used self-report measure that assesses the 17 DSM-IV PTSD symptoms. Responses to these questions are on a scale of 1 to 5 (&quot;not at all&quot; to &quot;extremely&quot;). A total symptom severity score (range from 17-85) can be calculated, with a higher score indicating higher symptom severity.</description>
        <time_frame>Baseline, Post-Treatment (approximately 4-months post treatment completion), 6-months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cognitive Behavioral Therapy + Treatment as Usual</title>
            <description>The experimental group will receive treatment as usual (TAU) plus cognitive behavioral therapy (CBT).
Cognitive behavioral therapy for PTSD: The CBT for PTSD model is based on modern theories of posttraumatic reactions that place a premium on the importance of individuals' appraisals of traumatic events, their own reactions and those of others, and the meaning of the experience in terms of oneself and one's place in the world. In addition, the model employs cognitive restructuring to teach individuals how to examine and challenge their trauma-related appraisals.</description>
          </group>
          <group group_id="O2">
            <title>Treatment as Usual</title>
            <description>The &quot;no intervention&quot; group will receive treatment as usual (TAU) without additional individual treatment..</description>
          </group>
        </group_list>
        <measure>
          <title>PTSD Checklist (PCL)</title>
          <description>A secondary measure of PTSD will be the PCL. The PCL is a widely used self-report measure that assesses the 17 DSM-IV PTSD symptoms. Responses to these questions are on a scale of 1 to 5 (&quot;not at all&quot; to &quot;extremely&quot;). A total symptom severity score (range from 17-85) can be calculated, with a higher score indicating higher symptom severity.</description>
          <units>score on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PCL Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.7" spread="9.2"/>
                    <measurement group_id="O2" value="62.1" spread="13.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PCL Post-Treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.3" spread="17.7"/>
                    <measurement group_id="O2" value="56.9" spread="15.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PCL 6-months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.7" spread="13.7"/>
                    <measurement group_id="O2" value="54.2" spread="16.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>.18</p_value>
            <p_value_desc>Post-Treatment P-Value.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed model p-values are adjusted for study site and baseline PCL score.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>.45</p_value>
            <p_value_desc>P-value at 6 months.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed model p-values are adjusted for study site and baseline PCL score.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>.73</p_value>
            <p_value_desc>Treatment main effect P-Value.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed model p-values are adjusted for study site and baseline PCL score.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>.63</p_value>
            <p_value_desc>Timepoint main effect P-Value</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed model p-values are adjusted for study site and baseline PCL score.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>.024</p_value>
            <p_value_desc>Interaction P-Value.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed model p-values are adjusted for study site and baseline PCL score.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>.15</p_value>
            <p_value_desc>Site main effect P-Value.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed model p-values are adjusted for study site and baseline PCL score.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Health Questionnaire-9 (PHQ-9)</title>
        <description>Patient Health Questionnaire-9 (PHQ-9): The PHQ-9 is adapted from the PRIME-MD. It can be used as a screen for depression or as a severity measure. The investigators used it as a measure of severity. The PHQ-9 score is on a range of 0 to 27, where a higher score indicates higher severity.</description>
        <time_frame>Baseline, Post-Treatment (approximately 4-months post treatment completion), 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cognitive Behavioral Therapy + Treatment as Usual</title>
            <description>The experimental group will receive treatment as usual (TAU) plus cognitive behavioral therapy (CBT).
Cognitive behavioral therapy for PTSD: The CBT for PTSD model is based on modern theories of posttraumatic reactions that place a premium on the importance of individuals' appraisals of traumatic events, their own reactions and those of others, and the meaning of the experience in terms of oneself and one's place in the world. In addition, the model employs cognitive restructuring to teach individuals how to examine and challenge their trauma-related appraisals.</description>
          </group>
          <group group_id="O2">
            <title>Treatment as Usual</title>
            <description>The &quot;no intervention&quot; group will receive treatment as usual (TAU) without additional individual treatment..</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Health Questionnaire-9 (PHQ-9)</title>
          <description>Patient Health Questionnaire-9 (PHQ-9): The PHQ-9 is adapted from the PRIME-MD. It can be used as a screen for depression or as a severity measure. The investigators used it as a measure of severity. The PHQ-9 score is on a range of 0 to 27, where a higher score indicates higher severity.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PHQ-9 Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.0" spread="4.7"/>
                    <measurement group_id="O2" value="14.8" spread="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PHQ-9 Post-Treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.0" spread="7.4"/>
                    <measurement group_id="O2" value="12.8" spread="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PHQ-9 6-months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.8" spread="17.1"/>
                    <measurement group_id="O2" value="12.2" spread="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>.48</p_value>
            <p_value_desc>Post-Treatment P-Value.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed model p-values are adjusted for study site and baseline PHQ score.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>.20</p_value>
            <p_value_desc>6-Month P-Value.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed model p-values are adjusted for study site and baseline PHQ score.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>.26</p_value>
            <p_value_desc>Treatment main effect P-Value.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed model p-values are adjusted for study site and baseline PHQ score.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>.71</p_value>
            <p_value_desc>Timepoint main effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed model p-values are adjusted for study site and baseline PHQ score.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>.56</p_value>
            <p_value_desc>Interaction main effect P-Value.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed model p-values are adjusted for study site and baseline PHQ score.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>.51</p_value>
            <p_value_desc>Site main effect P-Value.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed model p-values are adjusted for study site and baseline PHQ score.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Participants were monitored for both adverse events and serious adverse events (AE/SAE) once they were enrolled in the clinical trial. Assessors and clinical staff asked participants about any possible AE/SAE at post-assessment and 6-months. CBT+TAU clinical staff also asked participants about any AE/SAEs during their clinical sessions.</time_frame>
      <desc>Serious Adverse Events (SAEs) and Adverse Events (AEs) follow the definitions as outlined by clinicaltrials.gov but also VHA Handbook 1200.5:</desc>
      <group_list>
        <group group_id="E1">
          <title>Cognitive Behavioral Therapy (CBT) + Treatment as Usual (TAU)</title>
          <description>The experimental group will receive treatment as usual (TAU) plus cognitive behavioral therapy (CBT).
Cognitive behavioral therapy for PTSD: The CBT for PTSD model is based on modern theories of posttraumatic reactions that place a premium on the importance of individuals' appraisals of traumatic events, their own reactions and those of others, and the meaning of the experience in terms of oneself and one's place in the world. In addition, the model employs cognitive restructuring to teach individuals how to examine and challenge their trauma-related appraisals.</description>
        </group>
        <group group_id="E2">
          <title>Treatment as Usual (TAU)</title>
          <description>The &quot;no intervention&quot; group will receive treatment as usual (TAU).</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="64"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitalization due to hip replacement surgery</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>hospitalization due to syncopal episode</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mental Health Episode resulting in hospital encounter</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="64"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitalization for kidney failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Testicular and groin surgery resulting in inpatient hospital stay</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>inpatient stay for untreated COPD</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>incarceration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="64"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>hemophilia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>corneal abrasion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>ER visit due to dental pain and/or possible dental abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>chronic pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>testicular pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>motor vehicle accident which results in paralysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>musculature pain and discomfort</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="64"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>low back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mental Health and/or Substance Abuse ER visit</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="10"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>kidney stones</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Jail</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jessica L. Hamblen, PhD</name_or_title>
      <organization>VA National Center for PTSD</organization>
      <phone>8022965132</phone>
      <email>jessica.hamblen@va.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

